Connection

RADEK SKODA to Hematologic Neoplasms

This is a "connection" page, showing publications RADEK SKODA has written about Hematologic Neoplasms.
Connection Strength

2.086
  1. Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
    View in: PubMed
    Score: 0.560
  2. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 07 25; 213(8):1479-96.
    View in: PubMed
    Score: 0.406
  3. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015 Aug; 43(8):599-608.
    View in: PubMed
    Score: 0.379
  4. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011 Feb 10; 117(6):2075-6.
    View in: PubMed
    Score: 0.279
  5. Genomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.158
  6. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
    View in: PubMed
    Score: 0.122
  7. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
    View in: PubMed
    Score: 0.119
  8. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
    View in: PubMed
    Score: 0.065
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.